Standard

Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. / Tamkovich, Svetlana N.; Yunusova, Natalia V.; Tugutova, Elena et al.

In: Asian Pacific Journal of Cancer Prevention, Vol. 20, No. 1, 25.01.2019, p. 255-262.

Research output: Contribution to journalArticlepeer-review

Harvard

Tamkovich, SN, Yunusova, NV, Tugutova, E, Somov, AK, Proskura, KV, Kolomiets, LA, Stakheeva, MN, Grigor'eva, AE, Laktionov, PP & Kondakova, IV 2019, 'Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients', Asian Pacific Journal of Cancer Prevention, vol. 20, no. 1, pp. 255-262. https://doi.org/10.31557/APJCP.2019.20.1.255

APA

Tamkovich, S. N., Yunusova, N. V., Tugutova, E., Somov, A. K., Proskura, K. V., Kolomiets, L. A., Stakheeva, M. N., Grigor'eva, A. E., Laktionov, P. P., & Kondakova, I. V. (2019). Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. Asian Pacific Journal of Cancer Prevention, 20(1), 255-262. https://doi.org/10.31557/APJCP.2019.20.1.255

Vancouver

Tamkovich SN, Yunusova NV, Tugutova E, Somov AK, Proskura KV, Kolomiets LA et al. Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. Asian Pacific Journal of Cancer Prevention. 2019 Jan 25;20(1):255-262. doi: 10.31557/APJCP.2019.20.1.255

Author

Tamkovich, Svetlana N. ; Yunusova, Natalia V. ; Tugutova, Elena et al. / Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. In: Asian Pacific Journal of Cancer Prevention. 2019 ; Vol. 20, No. 1. pp. 255-262.

BibTeX

@article{d06cf2d8b2184fc4a0c9520f3f5e355e,
title = "Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients",
abstract = "Background: As is known, exosomes play an important role in promoting progression of cancers by increasing its invasive potential. The aim of this study was to evaluate the levels of tetraspanine-associated (ADAM-10) and tetraspanine-nonassociated proteases (20S proteasomes) in exosomes from culture medium, plasma exosomes of patients with breast tumors and plasma and ascites of ovarian tumor patients. Methods: MCF-7 and SVO-3 culture mediums and blood samples from healthy females (n = 30, HFs), patients with diffuse dyshormonal dysplasia of the breast (n=28, BBTPs), breast cancer patients (n=32, BCPs), borderline ovarian tumor patients (n=20, BOTPs) and blood and ascites samples ovarian cancer patients (n=35, OCPs) were included in the study. Exosomes from plasma, ascites and culture mediums were isolated and characterized in according to Extracellular Vesicles Society. The expression levels of 20S proteasome and ADAM-10 in exosomes were determined using flow cytometry and western blot analysis, correspondingly. Results: The subpopulation composition of the exosomes from MCF-7 culture medium and from blood plasma of HFs and breast diseases patients is similar, however CD9/CD24 subpopulation significantly increased at cell supernatant. The similar results was obtained for exosomes from SVO-3 medium and blood plasma and ascites of ovary tumor patients, but CD9/CD24 subpopulation significantly decreased at cells and illness samples, however CD63/CD24 exosomes increased significantly from cell supernatant. 20S proteasome level is significantly increased in exosomes from MCF-7 and SVO-3 culture medium, breast tumor patients and OCPs plasma in comparison to HUVEC culture medium and HFs plasma samples. At CD9-positive exosomes from BCPs plasma and MCF-7 was reveal a high expression of ADAM-10 and low expression is from BBDPs plasma and ovarian tumor patients plasma/ ascites samples. Exosomes from ascites OCP had high expression of ADAM-10 in the CD24-positive subpopulation. Conclusion: Breast and ovarian cancer development is connected with functioning of immune proteasome forms in plasma and ascites exosomes, while increased ADAM10 expression at CD9-positive exosome was associated with breast cancer and at CD24-positive subpopulation - with ovarian cancer. Obtained data confirm role of exosomal proteases in tumor progression.",
keywords = "20S proteasome, ADAM-10, Ascites, Breast cancer, Exosomes, Ovarian cancer, Plasma",
author = "Tamkovich, {Svetlana N.} and Yunusova, {Natalia V.} and Elena Tugutova and Somov, {Anton K.} and Proskura, {Ksenia V.} and Kolomiets, {Larisa A.} and Stakheeva, {Marina N.} and Grigor'eva, {Alina E.} and Laktionov, {Pavel P.} and Kondakova, {Irina V.}",
note = "Creative Commons Attribution License",
year = "2019",
month = jan,
day = "25",
doi = "10.31557/APJCP.2019.20.1.255",
language = "English",
volume = "20",
pages = "255--262",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "1",

}

RIS

TY - JOUR

T1 - Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients

AU - Tamkovich, Svetlana N.

AU - Yunusova, Natalia V.

AU - Tugutova, Elena

AU - Somov, Anton K.

AU - Proskura, Ksenia V.

AU - Kolomiets, Larisa A.

AU - Stakheeva, Marina N.

AU - Grigor'eva, Alina E.

AU - Laktionov, Pavel P.

AU - Kondakova, Irina V.

N1 - Creative Commons Attribution License

PY - 2019/1/25

Y1 - 2019/1/25

N2 - Background: As is known, exosomes play an important role in promoting progression of cancers by increasing its invasive potential. The aim of this study was to evaluate the levels of tetraspanine-associated (ADAM-10) and tetraspanine-nonassociated proteases (20S proteasomes) in exosomes from culture medium, plasma exosomes of patients with breast tumors and plasma and ascites of ovarian tumor patients. Methods: MCF-7 and SVO-3 culture mediums and blood samples from healthy females (n = 30, HFs), patients with diffuse dyshormonal dysplasia of the breast (n=28, BBTPs), breast cancer patients (n=32, BCPs), borderline ovarian tumor patients (n=20, BOTPs) and blood and ascites samples ovarian cancer patients (n=35, OCPs) were included in the study. Exosomes from plasma, ascites and culture mediums were isolated and characterized in according to Extracellular Vesicles Society. The expression levels of 20S proteasome and ADAM-10 in exosomes were determined using flow cytometry and western blot analysis, correspondingly. Results: The subpopulation composition of the exosomes from MCF-7 culture medium and from blood plasma of HFs and breast diseases patients is similar, however CD9/CD24 subpopulation significantly increased at cell supernatant. The similar results was obtained for exosomes from SVO-3 medium and blood plasma and ascites of ovary tumor patients, but CD9/CD24 subpopulation significantly decreased at cells and illness samples, however CD63/CD24 exosomes increased significantly from cell supernatant. 20S proteasome level is significantly increased in exosomes from MCF-7 and SVO-3 culture medium, breast tumor patients and OCPs plasma in comparison to HUVEC culture medium and HFs plasma samples. At CD9-positive exosomes from BCPs plasma and MCF-7 was reveal a high expression of ADAM-10 and low expression is from BBDPs plasma and ovarian tumor patients plasma/ ascites samples. Exosomes from ascites OCP had high expression of ADAM-10 in the CD24-positive subpopulation. Conclusion: Breast and ovarian cancer development is connected with functioning of immune proteasome forms in plasma and ascites exosomes, while increased ADAM10 expression at CD9-positive exosome was associated with breast cancer and at CD24-positive subpopulation - with ovarian cancer. Obtained data confirm role of exosomal proteases in tumor progression.

AB - Background: As is known, exosomes play an important role in promoting progression of cancers by increasing its invasive potential. The aim of this study was to evaluate the levels of tetraspanine-associated (ADAM-10) and tetraspanine-nonassociated proteases (20S proteasomes) in exosomes from culture medium, plasma exosomes of patients with breast tumors and plasma and ascites of ovarian tumor patients. Methods: MCF-7 and SVO-3 culture mediums and blood samples from healthy females (n = 30, HFs), patients with diffuse dyshormonal dysplasia of the breast (n=28, BBTPs), breast cancer patients (n=32, BCPs), borderline ovarian tumor patients (n=20, BOTPs) and blood and ascites samples ovarian cancer patients (n=35, OCPs) were included in the study. Exosomes from plasma, ascites and culture mediums were isolated and characterized in according to Extracellular Vesicles Society. The expression levels of 20S proteasome and ADAM-10 in exosomes were determined using flow cytometry and western blot analysis, correspondingly. Results: The subpopulation composition of the exosomes from MCF-7 culture medium and from blood plasma of HFs and breast diseases patients is similar, however CD9/CD24 subpopulation significantly increased at cell supernatant. The similar results was obtained for exosomes from SVO-3 medium and blood plasma and ascites of ovary tumor patients, but CD9/CD24 subpopulation significantly decreased at cells and illness samples, however CD63/CD24 exosomes increased significantly from cell supernatant. 20S proteasome level is significantly increased in exosomes from MCF-7 and SVO-3 culture medium, breast tumor patients and OCPs plasma in comparison to HUVEC culture medium and HFs plasma samples. At CD9-positive exosomes from BCPs plasma and MCF-7 was reveal a high expression of ADAM-10 and low expression is from BBDPs plasma and ovarian tumor patients plasma/ ascites samples. Exosomes from ascites OCP had high expression of ADAM-10 in the CD24-positive subpopulation. Conclusion: Breast and ovarian cancer development is connected with functioning of immune proteasome forms in plasma and ascites exosomes, while increased ADAM10 expression at CD9-positive exosome was associated with breast cancer and at CD24-positive subpopulation - with ovarian cancer. Obtained data confirm role of exosomal proteases in tumor progression.

KW - 20S proteasome

KW - ADAM-10

KW - Ascites

KW - Breast cancer

KW - Exosomes

KW - Ovarian cancer

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=85060542446&partnerID=8YFLogxK

U2 - 10.31557/APJCP.2019.20.1.255

DO - 10.31557/APJCP.2019.20.1.255

M3 - Article

C2 - 30678441

AN - SCOPUS:85060542446

VL - 20

SP - 255

EP - 262

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 1

ER -

ID: 18503147